Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593744 | 1.00 | ADORA1 (0.50) | ADORA1ADORA2AADORA2BADORA3TAS1R3 | |
| SCHEMBL5396369 | 1.00 | ADORA1 (0.50) | ADORA1ADORA2AADORA2BADORA3TAS1R3 | |
| SCHEMBL5409612 | 0.90 | ADORA1 (0.63) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5395711 | 0.89 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL14593749 | 0.89 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5395722 | 0.89 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5401260 | 0.88 | NT5E (0.52) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5409769 | 0.88 | ADORA2A (0.56) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5386756 | 0.88 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL9444432 | 0.83 | ABCB1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163928-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1590359-A2 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV Therapeutics Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004069185-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.